Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii

International Journal of Infectious Diseases

Volumn 41, Issue , 2015, Pages 42-49

  El Shazly, Sherief ^a,b   Dashti, Ali ^a   Vali, Leila ^a   Bolaris, Michael ^c   Ibrahim, Ashraf S ^b,d  

^a KUWAIT UNIVERSITY   (Kuwait)

^b St John's Cardiovascular Research Center   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acinetobacter baumannii; MLST; PFGE; lactamase

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; BACTERIAL DNA; TRANSPOSON;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME MECHANISM; GENE INSERTION SEQUENCE; GENETIC CODE; GENOTYPE; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; UNITED STATES; ACINETOBACTER INFECTIONS; CALIFORNIA; GENE EXPRESSION REGULATION; GENETICS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; TRANSPOSON;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; DNA TRANSPOSABLE ELEMENTS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; GENE EXPRESSION REGULATION, BACTERIAL; GENOTYPE; HOSPITALS; HUMANS; LOS ANGELES; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84947939909     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.10.016     Document Type: Article

References (69)

1. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:3471-3484.
2. Maragakis L.L., Tucker M.G., Miller R.G., Carroll K.C., Perl T.M. Incidence and prevalence of multidrug-resistant Acinetobacter using targeted active surveillance cultures. JAMA 2008, 299:2513-2514.
3. Maragakis L.L., Winkler A., Tucker M.G., Cosgrove S.E., Ross T., Lawson E., et al. Outbreak of multidrug-resistant Serratia marcescens infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2008, 29:418-423.
4. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43(Suppl 2):S43-S48.
5. Aronson N.E., Sanders J.W., Moran K.A. In harm's way: infections in deployed American military forces. Clin Infect Dis 2006, 43:1045-1051.
6. Harman D.R., Hooper T.I., Gackstetter G.D. Aeromedical evacuations from Operation Iraqi Freedom: a descriptive study. Mil Med 2005, 170:521-527.
7. Hinsley D.E., Phillips S.L., Clasper J.S. Ballistic fractures during the 2003 Gulf conflict: early prognosis and high complication rate. J R Army Med Corps 2006, 152:96-101.
8. Murray C.K., Roop S.A., Hospenthal D.R., Dooley D.P., Wenner k., Hammock J., et al. Bacteriology of war wounds at the time of injury. Mil Med 2006, 171:826-829.
9. Murray C.K., Yun H.C., Griffith M.E., Thompson B., Crouch H.K., Monson L.S., et al. Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med 2009, 174:598-604.
10. Perez F., Hujer A.M., Hulten E.A., Fishbain J., Hujer K.M., Aron D., et al. Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am J Infect Control 2010, 38:63-65.
11. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668.
12. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
13. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
14. Dizbay M., Tunccan O.G., Sezer B.E., Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010, 42:741-746.
15. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
16. Doi Y., Husain S., Potoski B.A., McCurry K.R., Paterson D.L. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009, 15:980-982.
17. Lautenbach E., Synnestvedt M., Weiner M.G., Bilker W.B., Vo L., Schein J., et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009, 30:1186-1192.
18. Metan G., Sariguzel F., Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009, 20:540-544.
19. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
20. Karageorgopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
21. Gardiner D., Dukart G., Cooper A., Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010, 50:229-238.
22. Park Y.K., Jung S.I., Park K.H., Cheong H.S., Peck K.R., Song J.H., et al. Independent emergence of colistin-resistant Acinetobacter spp isolates from Korea. Diagn Microbiol Infect Dis 2009, 64:43-51.
23. Adams M.D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., Bonomo R.A. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009, 53:3628-3634.
24. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008, 32:450-454.
25. Levin A.S., Barone A.A., Penco J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1011.
26. Oliveira M.S., Prado G.V., Costa S.F., Grinbaum R.S., Levin A.S. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008, 61:1369-1375.
27. Valencia R., Arroyo L.A., Conde M., Aldana J.M., Torres M.J., Fernández-Cuenca F., et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009, 30:257-263.
28. Pogue J.M., Mann T., Barber K.E., Kaye K.S. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther 2013, 11:383-393.
29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21. Wayne, PA: CLSI; 2012.
30. Blanco M., Alonso M.P., Nicolas-Chanoine M.H., Dahbi G., Mora A., Blanco J.E., et al. Molecular epidemiology of Escherichia coli producing extended-spectrum beta-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2009, 63:1135-1141.
31. Poirel L., Lagrutta E., Taylor P., Pham J., Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010, 54:4914-4916.
32. Cattoir V., Poirel L., Rotimi V., Soussy C.J., Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother 2007, 60:394-397.
33. Coelho A., González-López J.J., Miró E., Alonso-Tarrés C., Mirelis B., Larrosa M.N., et al. Characterization of the CTX-M-15-encoding gene in Klebsiella pneumoniae strains from the Barcelona metropolitan area: plasmid diversity and chromosomal integration. Int J Antimicrob Agents 2010, 36:73-78.
34. Giraud E., Brisabois A., Martel J.L., Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp suggest a counter selection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 1999, 43:2131-2137.
35. Pérez-Pérez F.J., Hanson N.D. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002, 40:2153-2162.
36. Poirel L., Bonnin R.A., Nordmann P. Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect Genet Evol 2012, 12:883-893.
37. Poirel L., Naas T., Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 2010, 54:24-38.
38. Evans B.A., Amyes S.G. OXA β-lactamases. Clin Microbiol Rev 2014, 27:241-263.
39. Kiratisin P., Apisarnthanarak A., Saifon P., Laesripa C., Kitphati R., Mundy L.M. The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum beta-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn Microbiol Infect Dis 2007, 58:349-355.
40. Mugnier P.D., Poirel L., Nordmann P. Functional analysis of insertion sequence ISAba1, responsible for genomic plasticity of Acinetobacter baumannii. J Bacteriol 2009, 191:2414-2418.
41. Ribot E.M., Fair M.A., Gautom R., Cameron D.N., Hunter S.B., Swaminathan B., Barrett T.J. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis 2006, 3:59-67.
42. Bao L., Peng R., Ren X., Ma R., Li J., Wang Y. Analysis of some common pathogens and their drug resistance to antibiotics. Pak J Med Sci 2013, 29:135-139.
43. Dashti A.A., Vali L., El-Shazly S., Jadaon M.M. The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait. BMC Microbiol 2014, 14:214. 10.1186/s12866-014-0214-6.
44. Sharma M., Pathak S., Srivastava P. Prevalence and antibiogram of extended spectrum β-lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res 2013, 7:2173-2177.
45. Sjölund-Karlsson M., Howie R., Rickert R., Krueger A., Tran T.T., Zhao S., et al. Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USA. Emerg Infect Dis 2010, 16:1789-1791.
46. Adams-Haduch J.M., Onuoha E.O., Bogdanovich T., Tian G.B., Marschall J., Urban C.M., et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol 2011, 49:3849-3854.
47. Lee G.C., Lawson K.A., Burgess D.S. Clinical epidemiology of carbapenem-resistant Enterobacteriaceae in community hospitals: a case-case-control study. Ann Pharmacother 2013, 47:1115-1121.
48. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. National Healthcare Safety Network Team, Erratum: Infect Control Hosp Epidemiol 2009;30:107.
49. Seifert H., Dolzani L., Bressan R., van der Reijden T., van Strijen B., Stefanik D., et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005, 43:4328-4335.
50. Singh A., Goering R.V., Simjee S., Foley S.L., Zervos M.J. Application of molecular techniques to the study of hospital infection. Clin Microbiol Rev 2006, 19:512-530.
51. Bartual S.G., Seifert H., Hippler C., Luzon M.A., Wisplinghoff H., Rodríguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005, 43:4382-4390. Erratum: J Clin Microbiol 2007;45:2101.
52. Diancourt L., Passet V., Nemec A., Dijkshoorn L., Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 2010, 5:e10034.
53. Urwin R., Maiden M.C. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol 2003, 11:479-487.
54. Luo G., Spellberg B., Gebremariam T., Lee H., Fu Y., French S.W., Ibrahim A.S. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother 2012, 67:1439-1445. 10.1093/jac/dks050.
55. Wright M.S., Haft D.H., Harkins D.M., Perez F., Hujer K.M., Bajaksouzian S., et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 2014, 5:e00963-e1013.
56. Opazo A., Vali L., Al Obaid K., Dashti A.A., Amyes S.G. Novel genetic structure harbouring blaPER-1 in ceftazidime-resistant Acinetobacter baumannii isolated from Kuwait. Int J Antimicrob Agents 2014, 43:383-384. 10.1016/j.ijantimicag.2014.01.001.
57. Shelburne S.A., Singh K.V., White A.C., Byrne L., Carmer A., Austin C., et al. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston. Texas. J Clin Microbiol 2008, 46:198-205.
58. Wisplinghoff H, Fresen MM, Higgins PG, Edmond MB, Wenzel RP, Stefanik D, et al. MLST-based molecular epidemiology of clinical Acinetobacter baumannii bloodstream isolates from 52 hospitals in the US, 2010. Abstract C2-590. Abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston, MA, USA.
59. Valentine S.C., Contreras D., Tan S., Real L.J., Chu S., Xu H.H. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County. California. J Clin Microbiol 2008, 46:2499-2507. 10.1128/JCM.00367-08.
60. Aly M., Tayeb H.T., AlJohani S.M., Alyamani E.J., Aldughaishem F., Alabdulkarim I., et al. Genetic diversity of OXA-51-like genes among multidrug-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur J Clin Microbiol Infect Dis 2014, 33:1223-1228. 10.1007/s10096-014-2068-0.
61. Rafei R., Dabboussi F., Hamze M., Eveillard M., Lemarié C., Gaultier M.P., et al. Molecular analysis of Acinetobacter baumannii strains isolated in Lebanon using four different typing methods. PLoS One 2014, 9:e115969. 10.1371/journal.pone.0115969.
62. Bakour S., Alsharapy S.A., Touati A., Rolain J.M. Characterization of Acinetobacter baumannii clinical isolates carrying bla (OXA-23) carbapenemase and 16S rRNA methylase armA genes in Yemen. Microb Drug Resist 2014, 20:604-609. 10.1089/mdr.2014.0018.
63. Villalón P., Valdezate S., Medina-Pascual M.J., Rubio V., Vindel A., Saez Nieto J.A. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J Clin Microbiol 2011, 49:875-882. 10.1128/JCM.01026-10.
64. Mezzatesta M.L., Caio C., Gona F., Cormaci R., Salerno I., Zingali T., et al. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs. Int J Antimicrob Agents 2014, 44:112-116. 10.1016/j.ijantimicag.2014.04.014.
65. Jeannot K., Diancourt L., Vaux S., Thouverez M., Ribeiro A., Coignard B., et al. Molecular epidemiology of carbapenem non-susceptible Acinetobacter baumannii in France. PLoS One 2014, 9:e115452. 10.1371/journal.pone.0115452.
66. Gogou V., Pournaras S., Giannouli M., Voulgari E., Piperaki E.T., Zarrilli R., Tsakris A. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother 2011, 66:2767-2772. 10.1093/jac/dkr390.
67. Matsui M., Suzuki S., Yamane K., Suzuki M., Konda T., Arakawa Y., Shibayama K. Distribution of carbapenem resistance determinants among epidemic and non-epidemic types of Acinetobacter species in Japan. J Med Microbiol 2014, 63(Pt 6):870-877. 10.1099/jmm.0.069138-0.
68. Chen C.M., Ke S.C., Li C.R., Chang C.C. The comparison of genotyping, antibiogram, and antimicrobial resistance genes between carbapenem-susceptible and -resistant Acinetobacter baumannii. Comp Immunol Microbiol Infect Dis 2014, 37:339-346. 10.1016/j.cimid 2014.10.002.
69. Hammerum A.M., Hansen F., Skov M.N., Stegger M., Andersen P.S., Holm A., et al. Investigation of a possible outbreak of carbapenem-resistant Acinetobacter baumannii in Odense, Denmark using PFGE, MLST and whole-genome-based SNPs. J Antimicrob Chemother 2015, 70:1965-1968. 10.1093/jac/dkv072.